Proactiveinvestors recommends
Stocktube video
13/10/2011

Fusion IP reports a full-year profit and revenue up 35%

View full size
Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
EPIC: FIP
Latest Price: 52.50p  (1.94% Ascending)
52-week High: 77.50p
52-week Low: 21.50p
Market Cap: 38.24M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Fusion IP
www.fusionip.co.uk

Fusion IP owns the rights to 100% of the university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to invest in some the world's most advanced and exciting science, turning world class research into business through the creation of a growing portfolio of companies, in fields as varied as drug discovery, alternative energy and engineering.

Full Fusion IP profile here
Is FIP a Buy, Sell or Hold?Get your FREE analysis of FIP
Pdf

Fusion IP up again as semiconductor spin-off racks up sales

2nd Feb 2012, 8:32 am by Philip Whiterow It was the third bullish update from a member of Fusion IP’s stable of companies this week.

Intellectual property group Fusion IP’s (LON:FIP) shares jumped by 15% as it said semiconductor testing equipment associate Mesuro racked up sales of US$1.25 million in its last quarter. 

It was the third bullish update from a member of Fusion IP’s stable of companies this week.

Mesuro is a spin-off from Cardiff University and focused on commercialising RF test and measurement technologies coming out the university's Centre for High Frequency Engineering.The latest orders came from three customers, Fusion IP said. It has a 47% shareholding in Mesuro.

Richard Emsley, chief executive of Mesuro said the sales demonstrated the huge potential of its RF technology.

It enables device manufacturers to obtain the very highest performance from their designs, maximise device efficiency, reduce power consumption and decrease time to market, he added.

David Baynes, Fusion’s chief executive, added:  "Mesuro is in a transformational year and these sales should be a stepping stone for the company to secure significant sales in 2012. We look forward to working with Mesuro to converting its highly promising pipeline in the coming year."

On Monday, Fusion announced that 43% -owned Diurnal, a drug developer, had achieved a significant milestone in the progression of Chronocort, a replacement cortisol. 

Yesterday, Fusion said Seren Photonics had also signed its first collaboration agreement for its LED technology.

Shares rose 10.2p to 77.7p and have more than tripled in the last six months.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.